Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PRO CAR 202

Next Previous
Drug Profile

PRO CAR 202

Alternative Names: IL-18 Armored CAR T for Prostate Cancer - PromiCell Therapeutics/Fred Hutchingson Cancer Research Center; IL-18 armored STEAP 1 CAR T cells - PromiCell Therapeutics/Fred Hutchingson Cancer Research Center; PRO CAR-202

Latest Information Update: 03 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Fred Hutchinson Cancer Research Center
  • Developer Fred Hutchinson Cancer Research Center; PromiCell Therapeutics
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; Interleukin 18 replacements; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Ewing's sarcoma; Prostate cancer

Most Recent Events

  • 03 Jul 2025 PromiCell Therapeutics intends to file an IND application for Prostrate Cancer (Metastatic disease, Hormone refractory, Adjuvant therapy) by late 2025 (PromiCell Therapeutics, July 2025)
  • 03 Jul 2025 PromiCell Therapeutics plans a phase I stuy for Prostrate Cancer (Metastatic disease, Hormone refractory, Adjuvant therapy) in early 2026 (PromiCell Therapeutics, July 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top